Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jon Best
11.05.26 -- Your CDMO Quality Dashboard Is Green. What's It Hiding?
Webinar: Beyond Destination and Delivery: Designing a Distribution Testing Program Can your pharmaceutical packaging withstand the journey to patients? From vibration and impact to temperature changes and handling, distribution hazards can compromise product quality and package integrity.
10.05.26 -- CDMOs Co-Author The RNA Ecosystem
Get more pharma outsourcing insight with our FREE newsletter Newsletter | October 5, 2026 Virtual Symposium: Developing Custom GMP Lipids: A Patient-Driven Partnership From concept to GMP, bringing a custom lipid to production takes more than technical expertise. It takes collaboration.
Top Four Things To Consider When Looking For A CDMO To Maximize Drug Substance Utilization
By Enda McKeon, Jon Best, and Jonathan Turkowski, AbbVie Efficiently managing drug substance during the fill/finish process is a vital driver of overall manufacturing optimization, particularly for advanced therapeutics with high production costs. Minimizing product loss requires a holistic look at equipment design, mechanical capabilities, and operational strategies. A primary consideration is the integration of advanced weight-checking technology.
Top Four Things To Consider When Looking For A CDMO To Maximize Drug Substance Utilization
By Enda McKeon, Jon Best, and Jonathan Turkowski, AbbVie Efficiently managing drug substance during the fill/finish process is a vital driver of overall manufacturing optimization, particularly for advanced therapeutics with high production costs. Minimizing product loss requires a holistic look at equipment design, mechanical capabilities, and operational strategies. A primary consideration is the integration of advanced weight-checking technology.
Top Four Things To Consider When Looking For A CDMO To Maximize Drug Substance Utilization
By Enda McKeon, Jon Best, and Jonathan Turkowski, AbbVie Efficiently managing drug substance during the fill/finish process is a vital driver of overall manufacturing optimization, particularly for advanced therapeutics with high production costs. Minimizing product loss requires a holistic look at equipment design, mechanical capabilities, and operational strategies. A primary consideration is the integration of advanced weight-checking technology.
01.08.25 -- The Building Blocks For Successful CDMO-Pharma Relationships For Packaging Operations
Let Us Handle Your Buffer Preparation Thermo Fisher Scientific is here to support you with the buffer preparation in your manufacturing workflow. Leaving the non-core activities to us enables you to focus on the patient therapy development. Our capabilities cover off-the-shelf products like WFI, NaOH, NaCl, or EtOH, a library of the most frequently used buffers that are made-to-order, as well as fully customized buffers.
AbbVie CMO: Your Expert Partner In Bringing Biologics To Market
By John Casey, Director, Biologics Contract Manufacturing, Jon Best, Director, Business Development The process of developing and manufacturing a monoclonal antibody (mAb) therapeutic can be overwhelming. With numerous variables impacting product quality, many organizations developing these complex molecules require proven expertise and support to timely deliver a safe, reliable therapeutic that meets patient needs.
02.05.24 -- Designing Facility Monitoring Systems For Cleanrooms
Inhalable mRNA With Ethris' Carsten Rudolph, Ph.D. On the Business of Biotech, we welcome Carsten Rudolph, Ph.D., co-founder and CEO of Ethris, a company developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines.
03.22.21 -- How Computational Drug Discovery Is Disrupting Biopharma
Newsletter | March 22, 2021 By Matthew Pillar, editor, BioProcess Online NeuBase Therapeutics CEO, Dr. Dietrich Stephan, discusses the important role computational drug discovery plays as we emerge from what he characterizes as “a decades long, multibillion-dollar chemical engineering escapade with a very low success rate to find one drug.” By Erich H. Bozenhardt and Herman F.
AbbVie Contract Manufacturing Services - BioProcess International
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people, and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology, and neuroscience.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jon
Contact Jon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack